[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
[PDF][PDF] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
N Sirichumroonwit, K Chanpiwat, AHR SM, RJ Storer… - covid-factuel.fr
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
[PDF][PDF] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
N Sirichumroonwit, K Chanpiwat, AHR SM, RJ Storer… - ris.cdu.edu.au
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
DL Wannigama, C Hurst, P Phattharapornjaroen… - eClinicalMedicine, 2024 - Elsevier
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
DL Wannigama, C Hurst, P Phattharapornjaroen… - …, 2024 - ncbi.nlm.nih.gov
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized …
COVID-EarlyMed Trial Team - eClinicalMedicine, 2024 - mahidol.elsevierpure.com
Background: Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
[PDF][PDF] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
N Sirichumroonwit, K Chanpiwat, AHR SM, RJ Storer… - researchgate.net
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized …
COVID-EarlyMed Trial Team - EClinicalMedicine, 2024 - researchers.cdu.edu.au
Background: Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
DL Wannigama, C Hurst, P Phattharapornjaroen… - …, 2024 - thelancet.com
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized …
DL Wannigama, C Hurst, P Phattharapornjaroen… - …, 2024 - europepmc.org
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …